5-ALA in Oncology: Current Clinical Applications, Biological Limitations, and Emerging Translational Strategies

Area of Science:

• Oncology
• Photodynamic Therapy
• Theranostics

Background:

• 5-Aminolevulinic acid (5-ALA) is selectively converted to protoporphyrin IX (PpIX) within cells.
• This conversion enables both photodynamic diagnosis (PDD) and photodynamic therapy (PDT) in oncology.
• 5-ALA's theranostic capabilities are being explored for various cancers.

Purpose of the Study:

• To review the biological mechanisms of 5-ALA metabolism and tumor accumulation.
• To summarize clinical applications of 5-ALA in oncology, focusing on specific cancer types.
• To discuss limitations and emerging advancements in 5-ALA-based therapies.

Main Methods:

• Narrative review of current scientific literature.
• Focus on biological mechanisms, clinical applications, and limitations of 5-ALA.
• Inclusion of emerging translational strategies and combination therapies.

Main Results:

• 5-ALA demonstrates established clinical utility in specific oncological indications.
• Key limitations include tumor hypoxia, light penetration, and PpIX accumulation variability.
• Advancements in drug delivery, nanotechnology, and combination therapies show promise.

Conclusions:

• 5-ALA is a valuable theranostic agent with established and emerging oncological applications.
• Addressing biological and technical limitations is crucial for expanding its clinical use.
• Further well-designed clinical studies are essential to validate new applications and optimize existing ones.